Patients with IgE-mediated allergic diseases (such as allergic rhinitis [AR)/rhinoconjunctivitis (ARC)] are highly susceptible to placebo and nocebo effects. Since AIT is a disease-modifying treatment option for patients with respiratory allergic diseases, accurate measurement of the placebo effect is critical. For adverse reactions to medicines, nocebo implies that patients are more likely to experience an adverse effect if they expect or are worried about the adverse effect. Hence, optimizing healthcare resources is imperative, given the increased healthcare costs.

IG Allergen Immunotherapy

Chair: Darío Antolín-Amérigo

Secretary: Oliver Pfaar